The U.S. Food and Drug Administration (FDA) has cleared the first continuous glucose monitors (CGMs) for over-the-counter sale—a major win for health freedom and common sense.
"Giving more individuals valuable information about their health, regardless of their access to a doctor or health insurance, is an important step forward in advancing health equity for U.S. patients," said Jeff Shuren, director of the FDA's Center for Devices and Radiological Health, in a press release announcing the change.
